From genomic insights to clinical hope: Targeting NEU1 in IgA nephropathy

• Published in: International immunopharmacology Vol. 132; p. 112051
• Main Authors: Zhao, Cong, Zhang, Mingzhu, Zhao, Leying, Sun, Weiwei
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 10.05.2024
• Subjects: Genome-wide association study; IgA nephropathy; Mendelian randomization; NEU1; Therapeutic target; GWAS; ATF6B; MR; IgAN; Mendelian randomization; pQTL; ER; Therapeutic target; IgA nephropathy; Genome-wide association study; SNP; NEU1; CFHR3; IVW-MRE; HSPA1A
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2024.112051

•NEU1 identified as a key pathogenic protein in IgAN via proteome-wide MR study.•Analysis reveals neuraminic acid-related metabolites do not mediate IgA Nephropathy.•Existing neuraminidase inhibitors show promise for IgAN. IgA Nephropathy (IgAN), the primary form of glomerulonephritis, presents significant clinical challenges due to its obscure pathogenesis and lack of targeted treatments. We conducted a proteome-wide Mendelian randomization (MR) study to identify therapeutic targets for IgAN. Utilizing a plasma proteome dataset comprising 4907 blood plasma proteins as the exposure variable, and renal biopsy-confirmed IgAN cases as the outcome, this study employed MR to pinpoint proteins potentially pathogenic to IgAN. The robustness of our findings was affirmed through external dataset validation, reverse causation testing, and Bayesian colocalization analysis. Additionally, we conducted phenotypic scanning and analyzed downstream metabolites to investigate candidate proteins's biological function. In our study, a significant association was identified between an increase in neuraminidase 1 (NEU1) expression and the risk of IgAN. Specifically, a one standard deviation increase in NEU1 expression was associated with an odds ratio of 11.80 for the development of IgAN (95% confidence interval: 4.03–34.54). This association was substantiated across various statistical models and external validations. Colocalization analysis indicated a shared causal variant between NEU1 expression and IgAN. Furthermore, an increased influenza risk associated with NEU1 was observed, supporting the therapeutic potential of NEU1 inhibitors for IgAN. However, our study found no significant role for neuraminic acid-related metabolites in IgAN's development, suggesting an independent pathway for NEU1′s influence. This study identifies NEU1 as a promising therapeutic target for IgAN, backed by robust genetic evidence. Future research should explore NEU1′s therapeutic potential in diverse populations and clinical scenarios, further establishing its role in IgAN.